Cumberland Partners Ltd Trims Stock Position in McKesson Corporation $MCK

Cumberland Partners Ltd reduced its stake in McKesson Corporation (NYSE:MCK) by 34.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 10,440 shares of the company’s stock after selling 5,380 shares during the quarter. Cumberland Partners Ltd’s holdings in McKesson were worth $8,065,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. J.W. Cole Advisors Inc. raised its holdings in McKesson by 35.3% during the third quarter. J.W. Cole Advisors Inc. now owns 5,089 shares of the company’s stock worth $3,931,000 after purchasing an additional 1,329 shares during the last quarter. Private Wealth Partners LLC increased its position in shares of McKesson by 5.6% in the third quarter. Private Wealth Partners LLC now owns 31,841 shares of the company’s stock valued at $24,598,000 after buying an additional 1,682 shares in the last quarter. AlphaQuest LLC raised its stake in shares of McKesson by 91.2% during the 3rd quarter. AlphaQuest LLC now owns 1,767 shares of the company’s stock worth $1,365,000 after buying an additional 843 shares during the last quarter. CW Advisors LLC boosted its position in shares of McKesson by 282.5% in the 2nd quarter. CW Advisors LLC now owns 11,008 shares of the company’s stock worth $8,067,000 after buying an additional 8,130 shares in the last quarter. Finally, Envestnet Asset Management Inc. grew its stake in McKesson by 12.4% in the 3rd quarter. Envestnet Asset Management Inc. now owns 330,647 shares of the company’s stock valued at $255,438,000 after acquiring an additional 36,451 shares during the last quarter. 85.07% of the stock is owned by institutional investors and hedge funds.

McKesson Stock Up 0.0%

Shares of NYSE:MCK opened at $946.52 on Thursday. The business has a fifty day simple moving average of $848.54 and a 200-day simple moving average of $793.10. McKesson Corporation has a 52 week low of $594.34 and a 52 week high of $971.93. The company has a market cap of $115.94 billion, a P/E ratio of 27.22, a P/E/G ratio of 1.52 and a beta of 0.40.

McKesson (NYSE:MCK) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, beating the consensus estimate of $9.19 by $0.15. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The company had revenue of $106.16 billion during the quarter, compared to analysts’ expectations of $105.98 billion. During the same quarter in the previous year, the business earned $8.03 EPS. The firm’s revenue was up 11.4% on a year-over-year basis. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. Sell-side analysts expect that McKesson Corporation will post 32.77 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 1st. Shareholders of record on Monday, March 2nd will be issued a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Monday, March 2nd. McKesson’s dividend payout ratio (DPR) is 9.43%.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. TD Cowen lifted their target price on shares of McKesson from $1,000.00 to $1,012.00 and gave the stock a “buy” rating in a research report on Thursday, February 5th. Robert W. Baird set a $968.00 target price on McKesson in a research note on Wednesday, January 14th. Wells Fargo & Company raised their price target on McKesson from $914.00 to $925.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 5th. JPMorgan Chase & Co. boosted their price target on McKesson from $983.00 to $1,107.00 and gave the stock an “overweight” rating in a report on Tuesday, February 10th. Finally, Weiss Ratings lowered McKesson from a “buy (a-)” rating to a “buy (b+)” rating in a research note on Thursday, February 5th. Thirteen equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, McKesson currently has a consensus rating of “Moderate Buy” and a consensus target price of $943.50.

Insider Transactions at McKesson

In related news, CAO Napoleon B. Rutledge, Jr. sold 328 shares of McKesson stock in a transaction on Friday, February 6th. The stock was sold at an average price of $955.00, for a total value of $313,240.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Thomas L. Rodgers sold 276 shares of the business’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $816.18, for a total value of $225,265.68. Following the sale, the executive vice president owned 2,268 shares of the company’s stock, valued at $1,851,096.24. The trade was a 10.85% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 794 shares of company stock worth $718,056 in the last ninety days. Insiders own 0.08% of the company’s stock.

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.